Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 669,268
  • Shares Outstanding, K 169,435
  • Annual Sales, $ 138,100 K
  • Annual Income, $ 31,870 K
  • EBIT $ 23 M
  • EBITDA $ 20 M
  • 60-Month Beta 2.37
  • Price/Sales 5.01
  • Price/Cash Flow 11.27
  • Price/Book 6.27

Options Overview Details

View History
  • Implied Volatility 147.13% (+15.33%)
  • Historical Volatility 92.56%
  • IV Percentile 49%
  • IV Rank 12.42%
  • IV High 550.81% on 03/26/25
  • IV Low 89.91% on 08/19/25
  • Expected Move (DTE 11) 0.64 (16.14%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 211
  • Volume Avg (30-Day) 951
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 25,518
  • Open Int (30-Day) 32,729
  • Expected Range 3.31 to 4.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 5
  • High Estimate -0.03
  • Low Estimate -0.10
  • Prior Year 0.22
  • Growth Rate Est. (year over year) -136.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.35 +17.91%
on 11/07/25
4.62 -14.50%
on 11/06/25
-0.26 (-6.18%)
since 11/05/25
3-Month
1.90 +107.89%
on 09/16/25
4.62 -14.50%
on 11/06/25
+1.67 (+73.25%)
since 09/05/25
52-Week
0.40 +887.50%
on 04/07/25
4.62 -14.50%
on 11/06/25
+2.79 (+240.52%)
since 12/05/24

Most Recent Stories

More News
CytomX Therapeutics to Present at Upcoming December Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management...

CTMX : 3.95 (-3.19%)
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean...

CTMX : 3.95 (-3.19%)
CytomX Therapeutics: Q3 Earnings Snapshot

CytomX Therapeutics: Q3 Earnings Snapshot

CTMX : 3.95 (-3.19%)
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC...

CTMX : 3.95 (-3.19%)
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

- CX-801 (PROBODY ® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism...

CTMX : 3.95 (-3.19%)
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will...

CTMX : 3.95 (-3.19%)
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment...

CTMX : 3.95 (-3.19%)
Oppenheimer Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on CytomX Therapeutics, with a price target of $7.00. The company’s shares opened today at $3.35.Elevate Your Investing...

CTMX : 3.95 (-3.19%)
CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management...

CTMX : 3.95 (-3.19%)
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company’s goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains...

CTMX : 3.95 (-3.19%)

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 4.22
2nd Resistance Point 4.15
1st Resistance Point 4.05
Last Price 3.95
1st Support Level 3.88
2nd Support Level 3.82
3rd Support Level 3.72

See More

52-Week High 4.62
Last Price 3.95
Fibonacci 61.8% 3.01
Fibonacci 50% 2.51
Fibonacci 38.2% 2.01
52-Week Low 0.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar